Skip to main content

Table 4 Predicted vs. actual costs in the validation/test population, by MS or general health score disease status tertilesa

From: Development and validation of a claims-based measure as an indicator for disease status in patients with multiple sclerosis treated with disease-modifying drugs

  Disease status tertile
Low Medium High
MS score
n 3902 3801 3682
Predicted costs, $
 Mean (SD) 5047 (2867) 8583 (5397) 20,743 (34,041)
 Median (IQR) 4269 (3393–5712) 7193 (5359–10,042) 12,941 (8926–21,055)
 Minimum 2149 2415 3642
 Maximum 55,398 82,177 1,046,113
Actual costs, $
 Mean (SD) 5143 (9204) 8923 (12,770) 18,176 (27,936)
 Median (IQR) 2688 (1065–6052) 5344 (2617–10,210) 10,215 (5212–19,976)
 Minimum 0 0 0
 Maximum 241,470 293,690 499,099
General health, score
n 4400 3426 3559
Predicted costs, $
 Mean (SD) 5243 (2630) 8202 (4413) 21,781 (34,500)
 Median (IQR) 4507 (3471–6260) 7175 (5239–10,019) 13,973 (9567–22,598)
 Minimum 2149 2638 3552
 Maximum 39,259 73,002 1,046,113
Actual costs, $
 Mean (SD) 5233 (7947) 8455 (10,609) 19,363 (29,432)
 Median (IQR) 2950 (1187–6195) 5510 (2686–10,350) 10,725 (5429–21,577)
 Minimum 0 0 0
 Maximum 133,669 135,713 499,099
  1. IQR interquartile range, MS multiple sclerosis, SD standard deviation
  2. aAll costs adjusted to 2015 US dollars using the medical care component of the Consumer Price Index